

- Please amend claims 12 and 14 to read as follows:

B 1

12.(once amended) A process for preparing a pharmaceutical composition of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter "Compound (I)") in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

- (i) preparing a first composition comprising Compound (I) in a pharmaceutically acceptable form and a first pharmaceutically acceptable carrier; and
- (ii) admixing the first composition with a second pharmaceutically acceptable carrier and thereafter formulating the composition produced into an administerable unit dosage form comprising 2 to 8 mg of Compound (I) in a pharmaceutically acceptable form.

B 2

14.(once amended) A process according to claim 12, wherein the administerable unit dosage form is a tablet.

Please add the following new claims:

B 3

23.(new) A process according to claim 12, wherein the first composition is in granular form.

24.(new) A process according to claim 12, wherein the first composition contains an amount of Compound (I) in a pharmaceutically acceptable form in the range of from 2 to 50% by weight.

25.(new) A process according to claim 12, wherein the first composition contains an amount of Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

26.(new) A process according to claim 23, wherein the first composition contains an amount of Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

27.(new) A process according to claim 12, wherein the first composition contains Compound (I) in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

28.(new) A process according to claim 27, wherein the first composition is in granular form.

29.(new) A process according to claim 28, wherein the first composition contains Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

30.(new) A process according to claim 12, wherein the pharmaceutically acceptable form of Compound (I) is a pharmaceutically acceptable salt.

31.(new) A process according to claim 30, wherein the salt is a maleate salt.

32.(new) A process according to claim 12, wherein the pharmaceutically acceptable form of Compound (I) is a pharmaceutically acceptable solvate.

33.(new) A process according to claim 32, wherein the solvate is a hydrate.

34.(new) A process according to claim 12, wherein the pharmaceutically acceptable form of Compound (I) is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

35.(new) A process according to claim 12, wherein the administerable unit dosage form comprises 2 mg of Compound (I) in a pharmaceutically acceptable form.

36.(new) A process according to claim 12, wherein the administerable unit dosage form comprises 4 mg of Compound (I) in a pharmaceutically acceptable form.

37.(new) A process according to claim 12, wherein the administerable unit dosage form comprises 8 mg of Compound (I) in a pharmaceutically acceptable form.

38.(new) A pharmaceutical composition formed by the process of claim 12.

39.(new) A pharmaceutical composition formed by the process of claim 29.

40.(new) A pharmaceutical composition formed by the process of claim 31.

41.(new) A process for preparing a pharmaceutical composition of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter "Compound (I)") in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

(i) preparing a first composition comprising Compound (I) in a pharmaceutically acceptable form and a first pharmaceutically acceptable carrier; and

(ii) admixing the first composition with a second pharmaceutically acceptable carrier and thereafter formulating the composition produced into an administerable unit dosage form comprising 1 to 8 mg of Compound (I) in a pharmaceutically acceptable form.

42.(new) A process according to claim 41, wherein the administerable unit dosage form is a tablet.

43.(new) A process according to claim 41, wherein the first composition is in granular form.

44.(new) A process according to claim 41, wherein the first composition contains an amount of Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

BB
cont
45.(new) A process according to claim 43, wherein the first composition contains an amount of Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

46.(new) A process according to claim 41, wherein the first composition contains Compound (I) in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

47.(new) A process according to claim 46, wherein the first composition is in granular form.

48.(new) A process according to claim 47, wherein the first composition contains Compound (I) in a pharmaceutically acceptable form in the range of from 5 to 20% by weight.

49.(new) A process according to claim 41, wherein the pharmaceutically acceptable form of Compound (I) is a pharmaceutically acceptable salt.

50.(new) A process according to claim 49, wherein the salt is a maleate salt.

51.(new) A process according to claim 41, wherein the administerable unit dosage form comprises 1 mg of Compound (I) in a pharmaceutically acceptable form.

52.(new) A pharmaceutical composition formed by the process of claim 41.

53.(new) A pharmaceutical composition formed by the process of claim 48.

54.(new) A pharmaceutical composition formed by the process of claim 50.

REMARKS

Upon entry of this amendment, claims 12, 14 and 23-54 will be pending in the application.

Claims 1-8 and 15-22 have been withdrawn from consideration by the Examiner as being drawn to a non-elected group, and are therefore being canceled. Claims 9-11 and 13 are also being canceled without prejudice or disclaimer.

Claim 12 is being amended to expressly set forth the chemical name for "Compound (I)", as defined on page 1, 2nd paragraph of the specification, i.e., 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.

Claim 12 is further amended to focus on a particular embodiment of the invention, and claim 14 is being amended in view of said amendment.

New claims 23-54 are being added to set forth further embodiments of the invention.

Support for these amendments is found, for example, in the claims as originally filed, and in the specification at page 1, paragraphs 4 and 5; page 2, paragraphs 1-9; page 4, line 1 through page 6; and Examples 1 and 2 on pages 9-10. No new matter is being added.

The changes to claims 12 and 14 made by this amendment are shown in the attachment entitled "Version to Show Changes Made".

The present claim amendments were made to better define particular embodiments of the invention, notwithstanding the Applicants' belief that the unamended claims would have been allowable, without acquiescing to any of the Examiner's arguments, and without waiving the right to prosecute the